Imfinzi: Global Drug Analysis (2017) with Forecasts to 2026 – ResearchAndMarkets.com

DUBLIN–()–The “Drug
Analysis: Imfinzi”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

AstraZeneca’s Imfinzi is a human monoclonal antibody targeting PD-L1.
Programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, are members
of the cluster of differentiation (CD)28 and B7 family. The B7 family
cell-surface molecules and the CTLA-4 family both regulate complex
signaling pathways that affect T-cell activation, tolerance, and
immunopathology. The pathways have a similar effect on T-cell immune
response but are distinct from each other (Keir et al., 2008).

Key Topics Covered:

Product Profiles

  • Imfinzi: Head and neck cancer
  • Imfinzi: Bladder cancer
  • Durvalumab: Non-small cell lung cancer (NSCLC)

List of Figures

Figure 1: Imfinzi for head and neck cancer – SWOT analysis

Figure 2: Drug assessment summary of Imfinzi for SCCHN

Figure 3: Drug assessment summary of Imfinzi for SCCHN

Figure 4: Imfinzi sales for SCCHN across the US, Japan, and five major
EU markets, by country, 2017-26

Figure 5: Imfinzi for urothelial bladder cancer – SWOT analysis

Figure 6: Drug assessment summary for Imfinzi in urothelial bladder
cancer

Figure 7: Drug assessment summary for Imfinzi in urothelial bladder
cancer

Figure 8: Durvalumab for non-small cell lung cancer – SWOT analysis

Figure 9: Drug assessment summary for durvalumab in non-small cell lung
cancer

List of Tables

Table 1: Imfinzi drug profile

Table 2: Imfinzi Phase III trials in head and neck cancer

Table 3: Imfinzi early-phase data in head and neck cancer

Table 4: Imfinzi sales for SCCHN across the US, Japan, and five major EU
markets, by country ($m), 2017-26

Table 5: Imfinzi patient numbers for SCCHN across the US, Japan, and
five major EU markets, by country, 2017-26

Table 6: Imfinzi drug profile

Table 7: Imfinzi pivotal trial data in urothelial bladder cancer

Table 8: Imfinzi ongoing late-phase trials in urothelial bladder cancer

Table 9: Durvalumab drug profile

Table 10: Durvalumab Phase III trials in non-small cell lung cancer

Table 11: Durvalumab early-phase data in non-small cell lung cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gb8pm2/imfinzi_global?w=4



Source link

more recommended stories

Social Media Auto Publish Powered By : XYZScripts.com
%d bloggers like this: